Ratings by Piper Sandler (Tyler M. Van Buren)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/19/2022 | Biohaven Pharmaceutical Holding | BHVN | Downgrade | Neutral (Overweight) |
148.01 (15.55) |
-89.49% | Details | |
| 10/5/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/21/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/23/2021 | County Bancorp | ICBK | Downgrade | Neutral (Overweight) |
23.39 (35.25) |
50.71% | Details | |
| 3/1/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2020 | BeiGene, Ltd. | BGNE | Downgrade | Underweight (Neutral) |
304.30 (184.71) |
-39.3% | Details | |
| 7/1/2020 | County Bancorp | ICBK | Maintain | Overweight (N/A) |
|
Details | ||
| 5/4/2020 | County Bancorp | ICBK | Maintain | Overweight (N/A) |
|
Details | ||
| 12/30/2019 | BeiGene, Ltd. | BGNE | Maintain | Neutral (N/A) |
|
Details | ||
| 12/16/2019 | BeiGene, Ltd. | BGNE | Downgrade | Neutral (Overweight) |
176.03 (184.71) |
4.93% | Details | |
| 11/1/2019 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2019 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2019 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 9/12/2018 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details |
